Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, J&J sign on to uninsured plan

Executive Summary

Pfizer and Johnson & Johnson are among the proponents of a multi-stakeholder agreement to expand health coverage to the uninsured; the broad-brush proposal, unveiled Jan. 18 by the Health Coverage Coalition for the Uninsured, advocates a two-phase process, starting with a "kids first" initiative to expand the State Children's Health Insurance Program. The second phase would expand Medicaid availability to adults and offer new tax credit incentives for employer-sponsored coverage. Two years in development, the policy statement "allows the new Congress to begin its work on health coverage for a proposal that already has the agreement of diverse advocates," the coalition states. Members also include America's Health Insurance Plans, UnitedHealth Group, AARP, the American Medical Association, and the U.S. Chamber of Commerce...

You may also be interested in...



Part D Success Will Enhance Pharma’s Political Effectiveness, Execs Predict

The pharmaceutical industry will draw on its achievements in helping develop the Medicare drug benefit as it faces health care reform and other political challenges following the upcoming presidential election, top Merck and Schering-Plough executives predict

Optibac Launches Natural Children’s Probiotic Immunity Supplement In Sustainable Pack

The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.

India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?

Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel